Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

Trial Profile

Phase 1 Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs APVO 210 (Primary)
  • Indications Psoriasis; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Aptevo Therapeutics
  • Most Recent Events

    • 06 Dec 2018 Status changed from planning to not yet recruiting.
    • 01 Dec 2018 New trial record
    • 14 Nov 2018 According to an Aptevo Therapeutics media release, company plans to initiate this study in the first quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top